Home Tags Lung cancer

Tag: Lung cancer

AbbVie Discontinues Research and Development Program for Rovalpituzumab Tesirine

MERU, a Phase III trial evaluating rovalpituzumab tesirine (Rova-T / SC16LD6.5; AbbVie) as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated...

WCLC 2019: Daiichi Sankyo to Present Late-breaking Results from U3-1402 and...

The World Health Organization (WHO) estimates that lung cancer causes 1.59 million deaths globally per year. Non-small cell lung cancer (NSCLC) accounts for 80%–90%...
General Views of the 55th Annual Meeting meeting of the American Society of Clinical Oncology. Photo Courtesy: © ASCO/Nick Agro 2019.

Preliminary Phase I Data for U3-1402 Shows Manageable Safety and Reduction...

Preliminary results from the dose escalation part of the phase I study with U3-1402, an investigational and potential first-in-class HER3 targeting antibody-drug conjugate or...
Featured Image: General views at the American Society for Clinical Oncology (ASCO) annual meeting. Courtesy: © ASCO/Max Gersh 2015. Used with permission.

Phase I Data for SAR408701 Supports Further Development in Lung Cancer

During the upcoming annual meeting American Society of Clinical Oncology (ASCO) in June 2019, Sanofi's oncology franchise will present a renewed strategy to address...

Researchers Find SCLC-biopsy Specimen Reliable for Evaluating DLL3 Expression

High levels of delta-like protein 3 or DLL3 in small-cell lung cancer or SCLC are correlated with poor survival trends.  Li-Xu Yan, MD, a...

Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...

Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...

Mersana’s XMT-1536 Demonstrates Anti-tumor Activity in Lung Cancer Patient-Derived Xenograft Studies

Encouraging data from preclinical studies presented at the 2016 IASLC 17th World Conference on Lung Cancer, in Vienna, Austria, suggests that Mersana Therapeutics' immunoconjugate XMT-1536...

Novel Targeted Treatment for Small Cell Lung Cancer Shows Promise

Small cell lung cancer or SCLC is an aggressive disease that is difficult to treat and is frequently only diagnosed when it has metastasized...

Sacituzumab govitecan (IMMU-132) Shows Positive Interim Phase II Results

Sacituzumab govitecan also known as IMMU-132, an antibody-drug conjugate being developed by Immunomedics, a clinical-stage biopharmaceutical company, continues to produce durable responses in patients with...

A New Dawn

It's a new dawn. It's a new day.These powerful words in one of my favorite songs ("Feeling Good") by American Singer Nina Simone, remind...